Serum albumin levels on admission are associated with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Angiology

Volumn 66, Issue 3, 2015, Pages 278-285

  Kurtul, Alparslan ^a   Ocek, Adil Hakan ^a   Murat, Sani Namik ^a   Yarlioglues, Mikail ^a   Demircelik, Muhammed Bora ^b   Duran, Mustafa ^a   Ergun, Gokhan ^a   Cay, Serkan ^c  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b TURGUT OZAL UNIVERSITY   (Turkey)

^c Yuksek Ihtisas Education and Research Hospital   (Turkey)

Author keywords

Acute myocardial infarction; No reflow phenomenon; Primary percutaneous coronary intervention; Serum albumin level

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE MB; CREATININE; FIBRINOLYTIC AGENT; HEMOGLOBIN; HEPARIN; SERUM ALBUMIN; TIROFIBAN; TROPONIN T; ALB PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANGIOCARDIOGRAPHY; ANGIOGRAPHY DEVICE; ARTICLE; CARDIAC PATIENT; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HEPARINIZATION; HOSPITAL ADMISSION; HUMAN; IMAGING SOFTWARE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; REFERENCE VALUE; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR PATENCY; ADVERSE EFFECTS; BLOOD; CHI SQUARE DISTRIBUTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; RADIOGRAPHY; RISK; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; ODDS RATIO; PATIENT ADMISSION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SERUM ALBUMIN; STROKE VOLUME; TREATMENT OUTCOME; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 84925581875     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714526035     Document Type: Article

References (44)

1. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. N Engl J Med. 1993;328(10):673-679.
2. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 2002;39(4):591-597.
3. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36(4):1202-1209.
4. Lee CH, Tse HF. Microvascular obstruction after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2010;75(3): 369-377.
5. Tesic MB, Stankovic G, Vukcevic V, Ostojic MC. The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction. Herz. 2010;35(2):114-118.
6. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72(7):950-957.
7. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105(5):656-662.
8. Peters T Jr. Serum albumin. Adv Protein Chem. 1985;37:161-245.
9. Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol. 1984;33(13):2083-2088.
10. Maalej N, Albrecht R, Loscalzo J, Folts JD. The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces. J Am Coll Cardiol. 1999;33(5):1408-1414.
11. Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets. 1996;7(3):125-137.
12. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985;38(10):1166-1171.
13. Joles JA, Willekes-Koolschijn N, Koomans HA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int. 1997;52(3):761-770.
14. Gillum RF, Makuc DM. Serum albumin, coronary heart disease, and death. Am Heart J. 1992;123(2):507-513.
15. Klonoff-Cohen H, Barrett-Connor EL, Edelstein SL. Albumin levels as a predictor of mortality in the healthy elderly. J Clin Epidemiol. 1992;45(3):207-212.
16. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP. The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial. Am J Epidemiol. 1991;134(11):1266-1277.
17. Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. 1989;2(8677):1434-1436.
18. Oduncu V, Erkol A, Karabay CY, et al. The prognostic value of serum albumin levels on admission in patients with acute STsegment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis. 2013; 24(2):88-94.
19. Schalk BW, Visser M, Bremmer MA, Penninx BW, Bouter LM, Deeg DJ. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: longitudinal aging study Amsterdam. Am J Epidemiol. 2006;164(10):969-677.
20. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl JMed. 1985;312(14):932-936.
21. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010;23(5):429-436.
22. Oduncu V, Erkol A, Tanalp AC, et al. In-hospital prognostic value of admission plasma B-type natriuretic peptide levels in patients undergoing primary angioplasty for acute ST-elevation myocardial infarction. Turk Kardiyol Dern Ars. 2011;39(7):540-548.
23. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/SCAI writing committee to update 2001 guidelines for percutaneous coronary intervention). Circulation. 2006;113(7):e166-e286.
24. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219-227.
25. SYNTAX Score Working Group. SYNTAX Score Calculator [online algorithm]. Available at: http://www.syntaxscore.com. Accessed December 1, 2013.
26. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms [review]. J Am Soc Echocardiogr. 1989;2(5): 358-367.
27. Reffelmann T, Kloner RA. The no-reflow phenomenon: basic science and clinical correlates. Heart. 2002;87(2):162-168.
28. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3(9):499-506.
29. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;46(2):284-290.
30. Topsakal R, Kaya MG, Karakaya E, et al. Relationship between no-reflow phenomenon and serotonin levels in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous intervention. Anadolu Kardiyol Derg. 2010;10(3): 253-259.
31. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91(11):2844-2850.
32. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477-1482.
33. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6): 448-454. Erratum in: N Engl J Med. 1999;340(17):1376.
34. Ganotakis ES, Vrentzos GE, Gazi IF, et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo. 2007;21(4): 685-694.
35. Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol. 2002;21(1):44-52.
36. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007;38(6):1873-1880.
37. Hartopo AB, Gharini PP, Setianto BY. Low serum albumin levels and in-hospital adverse outcomes in acute coronary syndrome. Int Heart J. 2010;51(4):221-226.
38. Ko YG, Jung JH, Park S, et al. Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol. 2006;112(1):66-71.
39. Botto N, Sbrana S, Trianni G, et al. An increased plateletleukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: a pathogenic role for "no-reflow" phenomenon? Int J Cardiol. 2007;117(1):123-130.
40. ZhangWJ, Frei B. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002;55(4):820-829.
41. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432-437.
42. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108(19):2317-2322.
43. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496-1508.
44. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557-567.